Cormedix Inc (STU:19KA)
€ 9.65 0.25 (2.66%) Market Cap: 601.04 Mil Enterprise Value: 558.66 Mil PE Ratio: 0 PB Ratio: 10.17 GF Score: 52/100

CorMedix Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 06:35PM GMT
Release Date Price: €4.06 (-10.18%)
Rahul Sood
RBC Capital Markets - Analyst

Welcome to the 2023 RBC Global Healthcare Conference. I'm Rahul Sood, managing director in the healthcare investment banking group. And I'm joined on the stage today by Joe Todisco, the CEO of CorMedix. Joe, thanks for joining.

Joe Todisco
CorMedix Inc. - CEO

Thank you.

Questions & Answers

Rahul Sood
RBC Capital Markets - Analyst

Okay. So for those of us who aren't familiar with the CorMedix story, can you please provide us with a brief intro of the company and the lead asset, DefenCath, specifically, how DefenCath differentiated from the current products and procedures in place to protect against catheter-related bloodstream infections?

Joe Todisco
CorMedix Inc. - CEO

All right. Sure. Thanks. Well, thanks, those of you that are in here, for joining.

So CorMedix is a pre-commercial stage biotech company. And our lead product, DefenCath, the NDA was just resubmitted to FDA this past Monday. So the product

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot